Rifaximin: A review of its use in the management of traveller's diarrhoea

Drugs

Volumn 65, Issue 12, 2005, Pages 1697-1713

  Robins, Gayle W ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA; LIVER ENZYME; MACROLIDE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; RNA POLYMERASE;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BETA CHAIN; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG EXCRETION; DRUG REEXPOSURE; DRUG TOLERABILITY; DYSENTERY; ESCHERICHIA COLI; FECES; FECES ANALYSIS; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GUATEMALA; HEMOGLOBIN DETERMINATION; HUMAN; IN VITRO STUDY; INDIA; INTESTINE FLORA; KENYA; LEUKOCYTE; LIPID DIET; MEXICO; MINIMUM INHIBITORY CONCENTRATION; OCCULT BLOOD; PATHOGENESIS; PERU; PROVOCATION TEST; REVIEW; RNA SYNTHESIS; SALMONELLA; SHIGELLA; SHIGELLA FLEXNERI; SHIGELLOSIS; THROMBOCYTE; TRAVELLER DIARRHEA;

ANTI-BACTERIAL AGENTS; BACTERIA; DIARRHEA; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RIFAMYCINS; TRAVEL;

CAMPYLOBACTER JEJUNI; ESCHERICHIA COLI; NEGIBACTERIA; SALMONELLA; SHIGELLA; SHIGELLA FLEXNERI;

EID: 23844445205     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565120-00011     Document Type: Review

References (57)

1. Ericsson CD. Travellers' diarrhoea. Int J Antimicrob Agents 2003 Feb; 21 (2): 116-24
2. Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers' diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S26-30
3. Okhuysen P, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774-8
4. Casburn-Jones AC, Farthing MJG. Traveler's diarrhea. Gastroenterol Hepatol 2004; 19 (6): 610-8
5. de Bruyn G. Diarrhoea. Clin Evid 2000; 3: 320-6
6. Vila J, Levy SB. Antimicrobial resistance. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers' diarrhea. Hamilton (ONT): BC Decker Inc., 2003: 58-75
7. Huang DB, DuPont HL. Rifaximin-a novel antimicrobial for enteric infections. J Infect 2005; 50: 97-106
8. DuPont HL. Treatment of travelers' diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S31-3
9. Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S34-9
10. Salix Pharmaceuticals Inc. XIFAXIN prescribing information, 2004 Jun [online]. Available from URL: http://www.salix.com [Accessed 2005 Feb 23]
11. Normix: summary of product characteristics. Italy: Alfa Wassermann S.p.A., 2005 Jun 1
12. Rifacol: summary of product characteristics. Greece: Alfa Wassermann S.p.A., 2001
13. Normix: summary of product characteristics. Czech Republic: Alfa Wassermann S.p.A., 2001
14. Flonorm: summary of product characteristics. Mexico: Alfa Wassermann S.p.A., 2003
15. Normix: product information leaflet. Lebanon: Alfa Wassermann S.p.A., 2002 Dec 18
16. Lormyx: product information leaflet. China: Alfa Wassermann S.p.A., 2004
17. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995 Mar; 49: 467-84
18. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity: a review. Chemotherapy 2005; 51 Suppl. 1: 67-72
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2005 Jan. Report no. M100-S15 (M7)
20. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 Jan; 45 (1): 212-6
21. Sierra JM, Ruiz J, Navia MM, et al. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 2001 Feb; 45 (2): 643-4
22. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 Dec 1; 33: 1807-15
23. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 May; 98: 1073-8
24. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 Nov; 10 (11): 1009-11
25. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12 (12): 979-81
26. Soro O, Pesce A, Raggi M, et al. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 1997; 3: 147-51
27. Taylor D, McKenzie R, Durbin A, et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin (200 mg TID) to prevent diarrhea in subjects challenged with Shigella flexneri 2a [abstract 2079 plus poster]. 53rd Meeting of the American Society of Tropical Medicine and Hygiene; 2004 Nov 7-11; Miami (FL)
28. Trapnell CB, Taylor DN, Montgomery C, et al. Systemic pharmacokinetics of rifaximin in subjects with shigellosis. Clin Pharmacol Ther 2005 Feb; 77 (2): 60
29. FDA. Medical review: application number 21-361. Clinical study RFID3001 [online]. Available from URL: http://www.fda.gov/cder/ [Accessed 2005 Apr 26]
30. Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14 (2): 51-6
31. Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998 Mar; 54: 91-3
32. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000 Aug; 44: 2205-6
33. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998; 59 (6): 708-14
34. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005 May 17; 142 (10): 805-12
35. Com-Nougue C, Rodary C, Patte C. How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma. Stat Med 1993; 12: 1353-64
36. Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004 Feb; 2 (2): 135-8
37. Vial P, Mathewson J, DuPont H, et al. Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli for patients with diarrhoea. J Clin Microbiol 1990; 28: 882-5
38. World Health Organization. WHO model prescribing information-drugs used in bacterial infections [online]. Available from URL: http://www.who.int/ medicines/library/bacterial_model_pres/bacterial_content.shtml [Accessed 2005 Feb 24]
39. Butterton JR, Calderwood SB. Acute infectious diarrheal diseases and bacterial food poisoning. In: Braunwald E, Fauci A, Hauser S, et al, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 834-9
40. Steffen R, Castelli F, Nothdurft H. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 2005; 12 (2): 102-7
41. Boedeker E. Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 2005; 21: 15-9
42. Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005 May 17; 142 (10): 861-2
43. DuPont HL. Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nat Clin Prac Gastroenterol Hepatol 2005 Apr; 2 (4): 191-8
44. Caeiro JP, DuPont HL. Management of travellers' diarrhoea. Drugs 1998; 56 (1): 73-81
45. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 1995; 41 Suppl. 1: 48-81
46. Bouckenooghe A, Kass B. General principles in self-treating travelers' diarrhea abroad. In: Ericsson CD, DuPont HL, Steffen RS, editors. Traveler's diarrhea. Hamilton (ONT): BC Decker Inc., 2003: 200-16
47. DuPont HL, Mattila L. Antimicrobial treatment: an algorithmic approach. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers' diarrhea. Hamilton (ONT): BC Decker Inc, 2003: 227-37
48. Gascon J, Corachan M. Aetiology, epidemiology, and manage-ment of traveller's diarrhoea. Rev Med Microbiol 2003; 14 (3): 73-8
49. Adachi JA, Ericsson CD, Jiang Z-D, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37: 1165-71
50. Isenbarger D, Hoge C, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002 Feb; 8 (2): 175-80
51. Hoge C, Gambel J, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5
52. DuPont H. Are quinolones (Q) the current empiric treatment of choice for travelers' diarrhea? [abstract no. SY07.01]. 8th Conference of the International Society of Travel Medicine; 2003 May 7-11; New York
53. Ericsson CD, DuPont HL. Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005; 51 Suppl. 1: 73-80
54. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl. 1: 36-66
55. Ericsson CD. Rifaximin: a new approach to the treatment of travelers' diarrhea. Conclusion. J Travel Med 2001 Dec; 8 Suppl. 2: S40
56. Ericsson CD, DuPont HL, Mathewson JJ, et al. Test-of-cure stool cultures for traveler's diarrhea. J Clin Microbiol 1988; 26 (5): 1047-9
57. Huang DB, Okhuysen PC, Jiang ZD, et al. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol 2004 Feb; 99 (2): 383-9